ulocuplumab (BMS-936564) / BMS 
Welcome,         Profile    Billing    Logout  
 28 Diseases   1 Trial   1 Trial   67 News 


12»
  • ||||||||||  ulocuplumab (BMS-936564) / BMS
    Combined CXCR-4 Inhibition with Novel Agent GPC-100 (burixafor) and Beta 2 Adrenergic Receptor Blockade Enhances Cytarabine Response for Acute Myeloid Leukemia Blasts on Stroma (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_5275;    
    P1
    Clinical trials of CXCR4 inhibitors have been conducted to mobilize AML out of the protected BM niche, including plerixafor with 7+3 or MEC, BL-8040 with cytarabine (araC), LY2510924 with idarubicin/araC, and ulocuplumab (human IgG4 antibody) with MEC...In addition, high throughput drug screening of AML on stroma, but not in suspension or on CXCL12 coated plates, revealed that combination of the CXCR4 inhibitor GPC-100 and beta blocker propranolol, with araC, increased drug sensitivity (reduced IC50 by ?4 to >10 fold) as compared to araC alone for AML cells on HS-5 human stromal cell line or autologous patient mesenchymal stromal cells...Conclusions : These studies support further investigation of whether simultaneous blockade of CXCR4 and ADRB2 may potentiate chemotherapy response in AML, perhaps by disrupting microenvironment mediated chemotherapy protection. Patients with new diagnosis AML may be more susceptible to this approach than R/R AML due to higher CXCR4 expression by both blasts and LSCs.
  • ||||||||||  Aphexda (motixafortide) / BioLineRx, Gloria Pharma, ulocuplumab (BMS-936564) / BMS
    Review, Journal:  Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies. (Pubmed Central) -  Aug 3, 2024   
    The information collectively emphasizes the potential of CXCR4 antagonists as a therapeutic strategy for hematologic malignancies, showcasing advancements in preclinical and clinical studies. As these therapeutic strategies progress through clinical trials, their potential to reshape the prognosis of hematologic malignancies will become increasingly apparent.
  • ||||||||||  ulocuplumab (BMS-936564) / BMS, Imbruvica (ibrutinib) / AbbVie, J&J
    Phase classification, Trial termination:  A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia (clinicaltrials.gov) -  May 3, 2024   
    P1,  N=13, Terminated, 
    As these therapeutic strategies progress through clinical trials, their potential to reshape the prognosis of hematologic malignancies will become increasingly apparent. Phase classification: P1/2 --> P1 | Active, not recruiting --> Terminated; Sponsor decision to end follow-up early
  • ||||||||||  Aphexda (motixafortide) / BioLineRx, Gloria Pharma, ulocuplumab (BMS-936564) / BMS
    Biomarker, Review, Journal:  Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM). (Pubmed Central) -  Mar 17, 2024   
    Inspired by developed CXCR4 antagonists, including plerixafor, ulocuplumab, and motixafortide, more small molecular antagonists or antibodies for pro-tumor chemokine ligands and their receptors can be developed and used in clinical practice. Along with inhibiting pro-tumor chemokines, studies suggest combining chemokines with chimeric antigen receptor (CAR)-T therapy is promising and efficient.
  • ||||||||||  Toward optimizing CXCR4 inhibition with beta adrenergic blockade to enhance chemotherapy response in acute myeloid leukemia (Section 29) -  Mar 5, 2024 - Abstract #AACR2024AACR_2576;    
    The CXCR4 inhibitor plerixafor is used to increase mobilization of peripheral blood stem cells in combination with filgrastim...These have included use of plerixafor with 7+3 or MEC, BL-8040 with cytarabine, and ulocuplumab with MEC...The objective of this preclinical study is to identify the AML patient population most likely to respond to CXCR4 inhibition, and the role of combined beta-adrenergic blockade, as the latter has been shown pre-clinically to augment mobilization of HSCs when combined with a CXCR4 inhibitor, GPC-100 (Sukhtankar et al... These studies support further investigation of whether simultaneous blockade of CXCR4 and ADBR2 may potentiate chemotherapy response in AML by limiting microenvironment mediated chemotherapy protection and reveal that patients with new diagnosis may be more susceptible to this approach.
  • ||||||||||  ulocuplumab (BMS-936564) / BMS
    CXCR4 Blockade Targets Progression of Primary T Cell Acute Lymphoblastic Leukemia () -  Nov 29, 2022 - Abstract #ASH2022ASH_7234;    
    D) Schematic of treatment with aCXCR4 Ab (MDX-1338) or isotype control. E-F) Kaplan-Meier survival graph (left) and peripheral blood levels of hCD45+ of NSG mice engrafted with primary adult (E) and pediatric (F) T-ALL samples and treated with aCXCR4 Ab or isotype control.
  • ||||||||||  Journal, IO biomarker:  Targeted Therapies and Emerging Novel Treatment Approaches for Waldenström Macroglobulinemia. (Pubmed Central) -  Jul 23, 2022   
    Novel and promising agents in this disease include next-generation covalent BTK inhibitors (eg, tirabrutinib, orelabrutinib), non-covalent BTK inhibitors (eg, pirtobrutinib, ARQ531), BCL-2 antagonists (eg, venetoclax), and CXCR4-targeted agents (eg, mavorixafor, ulocuplumab), among others. Future studies will focus on developing fixed-duration combinations regimens with these novel agents aimed at increasing durable responses while minimizing toxicity and cost.
  • ||||||||||  Review, Journal:  The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies. (Pubmed Central) -  Apr 8, 2022   
    Plerixafor, BKT140, LY2510924, PF-06747143, ulocuplumab, and NOX-A12 are among the most well-known CXCR4 and CXCL12 modulators that their therapeutic efficacies have been evaluated in different pre-clinical and clinical studies of hematologic malignancies. To have an overview of the importance of CXCL12/CXCR4 and CXCL12/CXCR7 axes in the pathogenesis of leukemia and to gather information about the latest advances as well as challenges in targeting these axes in clinical settings, the present review has begun with a discussion about how aberrant expression of CXCL12/CXCR4 and CXCL12/CXCR7 pathways might regulate leukemogenesis and ended by outlining the key news of preclinical and clinical investigations in leukemia treatment.
  • ||||||||||  Review, Journal:  Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions. (Pubmed Central) -  Sep 3, 2021   
    It is therefore of great interest to investigate CXCR4/CXCR7/CXCL12 modulators in clinical development, with several CXCR4 and CXCL12 modulators such as plerixafor, ulocuplumab, balixafortide, and olaptesed pegol having already reached this stage...Contrary to CXCR4 and CXCL12 modulators, CXCR7 modulators have, thus far, not been extensively studied. Therefore, more (pre)clinical investigations are needed.
  • ||||||||||  Arzerra (ofatumumab) / Novartis, Genmab
    Journal, IO biomarker:  Management of Waldenström macroglobulinemia in 2020. (Pubmed Central) -  May 11, 2021   
    Alkylating agents (bendamustine, cyclophosphamide), proteasome inhibitors (bortezomib, carfilzomib, ixazomib), anti-CD20 monoclonal antibodies (rituximab, ofatumumab), and Bruton tyrosine kinase (BTK) inhibitors (ibrutinib, acalabrutinib, zanubrutinib) are safe and highly effective treatment options in patients with WM. Because novel covalent and noncovalent BTK inhibitors (tirabrutinib, vecabrutinib, LOXO-305, ARQ-531), BCL2 antagonists (venetoclax), and CXCR4-targeting agents (ulocuplumab, mavorixafor) are undergoing clinical development in WM, the future of WM therapy certainly appears bright and hopeful.
  • ||||||||||  Clinical, Review, Journal:  At the bedside: Profiling and treating patients with CXCR4-expressing cancers. (Pubmed Central) -  May 6, 2021   
    To date, Sanofi Genzyme's plerixafor is the only marketed CXCR4 inhibitor (i.e., Food and Drug Administration-approved in 2008 for stem cell mobilization)...These small molecules, peptides, and Abs include balixafortide (POL6326, Polyphor), mavorixafor (X4P-001, X4 Pharmaceuticals), motixafortide (BL-8040, BioLineRx), LY2510924 (Eli Lilly), and ulocuplumab (Bristol-Myers Squibb)...Biol. xx: xx-xx; 2020.
  • ||||||||||  ulocuplumab (BMS-936564) / BMS
    Journal, IO Biomarker:  Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy. (Pubmed Central) -  Oct 16, 2020   
    Moreover, in assays in vitro, anti-CXCR4 blocking antibody (MDX1338) efficiently reduced migration and invasion of alveolar rhabdomyosarcoma RH30 cells...In this study, we propose a novel therapeutic approach based on anti-CXCR4 blocking antibody in combination with NKAE cell therapy to prevent rhabdomyosarcoma tumor implantation and lung metastasis. These results provide the first evidence for the efficacy of this combined immunotherapy for preventing sarcoma disease dissemination.
  • ||||||||||  Darzalex IV (daratumumab) / J&J, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Waldenström Macroglobulinemia – 2020 Update on Management and Future Directions () -  Sep 14, 2020 - Abstract #SOHO2020SOHO_311;    
    Importantly, TTR was not affected by CXCR4 mutation status.19 Also promising is the second generation BTK inhibitor, zanubrutinib...However, most compelling is the MRR of 50% seen in the MYD88WT cohort, with a VGPR rate of 26.9% and a 12-month PFS of 72%.20 Other promising agents under study include next generation BTK and BCL2 inhibitors, CXCR4 inhibitors (e.g., ulocuplumab) and ERK pathway inhibitors, as well as the anti-CD38 monoclonal antibody, daratumumab, and CAR-T cell therapies. The development of these and other novel agents will usher in a new era in the treatment of Waldenström macroglobulinemia.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Review, Journal, IO biomarker:  What is new in the treatment of Waldenstrom macroglobulinemia? (Pubmed Central) -  Jun 4, 2020   
    The present Perspective would focus on exciting treatment strategies under development for WM patients, such as proteasome inhibitors (e.g., ixazomib), BTK inhibitors (e.g., acalabrutinib, zanubrutinib, vecabrutinib), BCL2 inhibitors (e.g., venetoclax), and anti-CXCR4 antibodies (e.g., ulocuplumab), among others. It is certainly an exciting time for WM therapy development with novel and promising treatment options in the horizon.
  • ||||||||||  ulocuplumab (BMS-936564) / BMS
    Biomarker, Preclinical, Journal:  CXCR4 in human osteosarcoma malignant progression. The response of osteosarcoma cell lines to the fully human CXCR4 antibody MDX1338. (Pubmed Central) -  Jun 14, 2019   
    Our data suggest that the response to anti-CXCR4 agents could be influenced by the genetic background and labeling profile which induces a different cross-talk between tumour cells and environment. The delay in cell cycle progression associated with increased apoptosis could sensitize p53-positive cells to conventional therapy and in vivo preclinical experiments are on going with the aim to suggest new combined target therapies in human OS.
  • ||||||||||  ulocuplumab (BMS-936564) / BMS, Opdivo (nivolumab) / BMS
    Enrollment change, Trial termination, Trial primary completion date:  CXCessoR4: Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors (clinicaltrials.gov) -  Mar 13, 2017   
    P1/2,  N=36, Terminated, 
    Active, not recruiting --> Recruiting N=195 --> 36 | Recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Jan 2017; Trial terminated because of lack of efficacy in the short term acute phase